Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Armata Pharmaceuticals (ARMP) EBIT (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed EBIT for 6 consecutive years, with -$2.8 million as the latest value for Q4 2018.

  • Quarterly EBIT fell 18.14% to -$2.8 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$11.1 million through Dec 2018, up 31.16% year-over-year, with the annual reading at -$36.6 million for FY2025, 13.67% up from the prior year.
  • EBIT hit -$2.8 million in Q4 2018 for Armata Pharmaceuticals, down from -$2.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$746000.0 in Q3 2017 to a low of -$11.9 million in Q4 2016.
  • Historically, EBIT has averaged -$3.7 million across 5 years, with a median of -$2.9 million in 2015.
  • Biggest five-year swings in EBIT: crashed 303.54% in 2016 and later skyrocketed 80.07% in 2017.
  • Year by year, EBIT stood at -$2.6 million in 2014, then dropped by 13.21% to -$2.9 million in 2015, then plummeted by 303.54% to -$11.9 million in 2016, then surged by 80.07% to -$2.4 million in 2017, then dropped by 18.14% to -$2.8 million in 2018.
  • Business Quant data shows EBIT for ARMP at -$2.8 million in Q4 2018, -$2.4 million in Q3 2018, and -$2.8 million in Q2 2018.